Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review
- PMID: 12123328
- DOI: 10.1093/annonc/mdf167
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review
Abstract
Background: The aim of this systematic review was to summarise and appraise the published evidence with regard to the frequency and risk factors of subclinical cardiotoxicity in apparently healthy survivors of childhood cancer after anthracycline therapy.
Patients and methods: A search was made in Medline for studies published between 1966 and May 2001 that included >50 children and reported on the frequency of measures of subclinical cardiotoxicity. Information about the studies was abstracted by two reviewers and a validity score was calculated for each study.
Results: The reported frequency of subclinical cardiotoxicity varied between 0% and 57% in the 25 studies included. Differences in outcome definitions of subclinical cardiotoxicity and differences in study patients with respect to the dose of anthracycline seemed to explain part of the wide variance of the frequency of subclinical cardiotoxicity. Fourteen of the 25 studies showed serious methodological limitations.
Conclusions: The reported frequency of subclinical cardiotoxicity shows a wide variation. Well designed studies with accurate and precise outcome measurements in well described groups of patients, after a sufficiently long follow-up period, are needed to obtain more insight into the frequency and importance of risk factors, and the clinical consequences of anthracycline-related subclinical cardiotoxicity.
Similar articles
-
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2. Cochrane Database Syst Rev. 2022. PMID: 36162822 Free PMC article.
-
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005008. doi: 10.1002/14651858.CD005008.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2009 Oct 07;(4):CD005008. doi: 10.1002/14651858.CD005008.pub3. PMID: 17054232 Updated.
-
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005006. doi: 10.1002/14651858.CD005006.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006. doi: 10.1002/14651858.CD005006.pub3. PMID: 17054231 Updated.
-
Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.Health Technol Assess. 2007 Jul;11(27):iii, ix-x, 1-84. doi: 10.3310/hta11270. Health Technol Assess. 2007. PMID: 17610809
-
Eliciting adverse effects data from participants in clinical trials.Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2. Cochrane Database Syst Rev. 2018. PMID: 29372930 Free PMC article.
Cited by
-
Cancer pharmacogenomics in children: research initiatives and progress to date.Paediatr Drugs. 2013 Apr;15(2):71-81. doi: 10.1007/s40272-013-0021-9. Paediatr Drugs. 2013. PMID: 23529868 Review.
-
The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer.Eur J Pediatr. 2003 Oct;162(10):690-6. doi: 10.1007/s00431-003-1275-y. Epub 2003 Aug 7. Eur J Pediatr. 2003. PMID: 12905011
-
Cardio-toxicity in childhood cancer survivors "Cure is not enough".J Thorac Dis. 2018 Dec;10(Suppl 35):S4344-S4350. doi: 10.21037/jtd.2018.11.28. J Thorac Dis. 2018. PMID: 30701102 Free PMC article. Review.
-
Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors.Clin Cancer Res. 2014 Dec 15;20(24):6314-23. doi: 10.1158/1078-0432.CCR-13-3490. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947931 Free PMC article.
-
Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors.Eur Heart J Cardiovasc Imaging. 2021 Mar 22;22(4):435-442. doi: 10.1093/ehjci/jeaa093. Eur Heart J Cardiovasc Imaging. 2021. PMID: 32535624 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
